Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2022) 4190-4198].
Chichili GR, Smulders R, Santos V, Cywin B, Kovanda L, Van Sant C, Malinoski F, Sebastian S, Siber G, Malley R. Chichili GR, et al. Among authors: siber g. Vaccine. 2024 Oct 3;42(23):126023. doi: 10.1016/j.vaccine.2024.05.071. Epub 2024 Jun 18. Vaccine. 2024. PMID: 38897894 Free article. No abstract available.
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
Roa CC Jr, de Los Reyes MRA, Plennevaux E, Smolenov I, Hu B, Gao F, Ilagan H, Ambrosino D, Siber G, Clemens R, Han HH. Roa CC Jr, et al. Among authors: siber g. Hum Vaccin Immunother. 2024 Dec 31;20(1):2301632. doi: 10.1080/21645515.2023.2301632. Epub 2024 Jan 11. Hum Vaccin Immunother. 2024. PMID: 38206168 Free PMC article. Clinical Trial.
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Buntinx E, Brochado L, Borja-Tabora C, Yu CY, Alberto ER, Montellano MEB, Carlos JC, Toloza LB, Hites M, Siber G, Clemens R, Ambrosino D, Qin H, Chen HL, Han HH, Hu B, Li P, Baccarini C, Smolenov I. Buntinx E, et al. Among authors: siber g. Vaccine. 2023 Mar 10;41(11):1875-1884. doi: 10.1016/j.vaccine.2023.02.017. Epub 2023 Feb 9. Vaccine. 2023. PMID: 36781334 Free PMC article. Clinical Trial.
Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021.
Gilbert PB, Isbrucker R, Andrews N, Goldblatt D, Heath PT, Izu A, Madhi SA, Moulton L, Schrag SJ, Shang N, Siber G, Sobanjo-Ter Meulen A. Gilbert PB, et al. Among authors: siber g. Vaccine. 2022 Jul 30;40(32):4283-4291. doi: 10.1016/j.vaccine.2022.05.016. Epub 2022 Jun 29. Vaccine. 2022. PMID: 35779963 Free PMC article.
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
Smolenov I, Han HH, Li P, Baccarini C, Verhoeven C, Rockhold F, Clemens SAC, Ambrosino D, Richmond P, Siber G, Liang J, Clemens R; SPECTRA Study Group. Smolenov I, et al. Among authors: siber g. Lancet Infect Dis. 2022 Jul;22(7):990-1001. doi: 10.1016/S1473-3099(22)00144-X. Epub 2022 Apr 18. Lancet Infect Dis. 2022. PMID: 35447085 Free PMC article. Clinical Trial.
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, Clemens SAC, Roa C Jr, Borja-Tabora C, Quinsaat A, Lopez P, López-Medina E, Brochado L, Hernández EA, Reynales H, Medina T, Velasquez H, Toloza LB, Rodriguez EJ, de Salazar DIM, Rodríguez CA, Sprinz E, Cerbino-Neto J, Luz KG, Schwarzbold AV, Paiva MS, Carlos J, Montellano MEB, de Los Reyes MRA, Yu CY, Alberto ER, Panaligan MM, Salvani-Bautista M, Buntinx E, Hites M, Martinot JB, Bhorat QE, Badat A, Baccarini C, Hu B, Jurgens J, Engelbrecht J, Ambrosino D, Richmond P, Siber G, Liang J, Clemens R. Bravo L, et al. Among authors: siber g. Lancet. 2022 Jan 29;399(10323):461-472. doi: 10.1016/S0140-6736(22)00055-1. Epub 2022 Jan 20. Lancet. 2022. PMID: 35065705 Free PMC article. Clinical Trial.
197 results